Related Research Articles
Enzymes are proteins that act as biological catalysts by accelerating chemical reactions. The molecules upon which enzymes may act are called substrates, and the enzyme converts the substrates into different molecules known as products. Almost all metabolic processes in the cell need enzyme catalysis in order to occur at rates fast enough to sustain life. Metabolic pathways depend upon enzymes to catalyze individual steps. The study of enzymes is called enzymology and the field of pseudoenzyme analysis recognizes that during evolution, some enzymes have lost the ability to carry out biological catalysis, which is often reflected in their amino acid sequences and unusual 'pseudocatalytic' properties.
In the fields of biochemistry and pharmacology an allosteric regulator is a substance that binds to a site on an enzyme or receptor distinct from the active site, resulting in a conformational change that alters the protein's activity, either enhancing or inhibiting its function. In contrast, substances that bind directly to an enzyme's active site or the binding site of the endogenous ligand of a receptor are called orthosteric regulators or modulators.
In biology and biochemistry, the active site is the region of an enzyme where substrate molecules bind and undergo a chemical reaction. The active site consists of amino acid residues that form temporary bonds with the substrate, the binding site, and residues that catalyse a reaction of that substrate, the catalytic site. Although the active site occupies only ~10–20% of the volume of an enzyme, it is the most important part as it directly catalyzes the chemical reaction. It usually consists of three to four amino acids, while other amino acids within the protein are required to maintain the tertiary structure of the enzymes.
Pyruvate kinase is the enzyme involved in the last step of glycolysis. It catalyzes the transfer of a phosphate group from phosphoenolpyruvate (PEP) to adenosine diphosphate (ADP), yielding one molecule of pyruvate and one molecule of ATP. Pyruvate kinase was inappropriately named before it was recognized that it did not directly catalyze phosphorylation of pyruvate, which does not occur under physiological conditions. Pyruvate kinase is present in four distinct, tissue-specific isozymes in animals, each consisting of particular kinetic properties necessary to accommodate the variations in metabolic requirements of diverse tissues.
In biochemistry and molecular biology, a binding site is a region on a macromolecule such as a protein that binds to another molecule with specificity. The binding partner of the macromolecule is often referred to as a ligand. Ligands may include other proteins, enzyme substrates, second messengers, hormones, or allosteric modulators. The binding event is often, but not always, accompanied by a conformational change that alters the protein's function. Binding to protein binding sites is most often reversible, but can also be covalent reversible or irreversible.
In biochemistry, a phosphatase is an enzyme that uses water to cleave a phosphoric acid monoester into a phosphate ion and an alcohol. Because a phosphatase enzyme catalyzes the hydrolysis of its substrate, it is a subcategory of hydrolases. Phosphatase enzymes are essential to many biological functions, because phosphorylation and dephosphorylation serve diverse roles in cellular regulation and signaling. Whereas phosphatases remove phosphate groups from molecules, kinases catalyze the transfer of phosphate groups to molecules from ATP. Together, kinases and phosphatases direct a form of post-translational modification that is essential to the cell's regulatory network.
Sir Alan Roy Fersht is a British chemist at the MRC Laboratory of Molecular Biology, Cambridge, and an Emeritus Professor in the Department of Chemistry at the University of Cambridge. He was Master of Gonville and Caius College, Cambridge from 2012 to 2018. He works on protein folding, and is sometimes described as a founder of protein engineering.
A catalytic triad is a set of three coordinated amino acid residues that can be found in the active site of some enzymes. Catalytic triads are most commonly found in hydrolase and transferase enzymes. An acid-base-nucleophile triad is a common motif for generating a nucleophilic residue for covalent catalysis. The residues form a charge-relay network to polarise and activate the nucleophile, which attacks the substrate, forming a covalent intermediate which is then hydrolysed to release the product and regenerate free enzyme. The nucleophile is most commonly a serine or cysteine, but occasionally threonine or even selenocysteine. The 3D structure of the enzyme brings together the triad residues in a precise orientation, even though they may be far apart in the sequence.
In biochemistry, a conformational change is a change in the shape of a macromolecule, often induced by environmental factors.
Allosteric enzymes are enzymes that change their conformational ensemble upon binding of an effector which results in an apparent change in binding affinity at a different ligand binding site. This "action at a distance" through binding of one ligand affecting the binding of another at a distinctly different site, is the essence of the allosteric concept. Allostery plays a crucial role in many fundamental biological processes, including but not limited to cell signaling and the regulation of metabolism. Allosteric enzymes need not be oligomers as previously thought, and in fact many systems have demonstrated allostery within single enzymes. In biochemistry, allosteric regulation is the regulation of a protein by binding an effector molecule at a site other than the enzyme's active site.
Carolyn Ruth Bertozzi is an American chemist and Nobel laureate, known for her wide-ranging work spanning both chemistry and biology. She coined the term "bioorthogonal chemistry" for chemical reactions compatible with living systems. Her recent efforts include synthesis of chemical tools to study cell surface sugars called glycans and how they affect diseases such as cancer, inflammation, and viral infections like COVID-19. At Stanford University, she holds the Anne T. and Robert M. Bass Professorship in the School of Humanities and Sciences. Bertozzi is also an Investigator at the Howard Hughes Medical Institute (HHMI) and is the former director of the Molecular Foundry, a nanoscience research center at Lawrence Berkeley National Laboratory.
KRAS is a gene that provides instructions for making a protein called K-Ras, a part of the RAS/MAPK pathway. The protein relays signals from outside the cell to the cell's nucleus. These signals instruct the cell to grow and divide (proliferate) or to mature and take on specialized functions (differentiate). It is called KRAS because it was first identified as a viral oncogene in the KirstenRAt Sarcoma virus. The oncogene identified was derived from a cellular genome, so KRAS, when found in a cellular genome, is called a proto-oncogene.
Malate dehydrogenase, mitochondrial also known as malate dehydrogenase 2 is an enzyme that in humans is encoded by the MDH2 gene.
In molecular biology, proteins are generally thought to adopt unique structures determined by their amino acid sequences. However, proteins are not strictly static objects, but rather populate ensembles of conformations. Transitions between these states occur on a variety of length scales and time scales , and have been linked to functionally relevant phenomena such as allosteric signaling and enzyme catalysis.
Stephen James Benkovic is an American chemist known for his contributions to the field of enzymology. He holds the Evan Pugh University Professorship and Eberly Chair in Chemistry at The Pennsylvania State University. He has developed boron compounds that are active pharmacophores against a variety of diseases. Benkovic has concentrated on the assembly and kinetic attributes of the enzymatic machinery that performs DNA replication, DNA repair, and purine biosynthesis.
Lorena Beese is a James B. Duke Professor of Biochemistry and Duke Cancer Institute Member. Her research involves structural mechanisms underlying DNA replication and repair, neurodegenerative diseases, cancer, and microbial pathogenesis; X-ray crystallography and cryo-electron microscopy; structure-based drug design; protein-protein and protein-nucleic acid interactions, enzyme mechanisms, chemical biology, protein structure and function.
Ruth Nussinov is an Israeli-American biologist born in Rehovot who works as a professor in the Department of Human Genetics, School of Medicine at Tel Aviv University and is the senior principal scientist and principal investigator at the National Cancer Institute, National Institutes of Health. Nussinov is also the editor in chief of the Current Opinion in Structural Biology and formerly of the journal PLOS Computational Biology.
Craig M. Crews is an American scientist at Yale University known for his contributions to chemical biology. He is known for his contributions to the field of induced proximity through his work in creating heterobifunctional molecules that "hijack" cellular processes by inducing the interaction of two proteins inside a living cell. His initial work focused on the discovery of PROteolysis-TArgeting Chimeras (PROTACs) to trigger degradation of disease-causing proteins, a process known as targeted protein degradation (TPD), and he has since developed new versions of -TACs to leverage other cellular processes and protein families to treat disease.
Erin Margaret Schuman, born May 15, 1963, in California, US, is a neurobiologist who studies neuronal synapses. She is currently a Director at the Max Planck Institute for Brain Research.
Edith Wilson Miles is a biochemist known for her work on the structure and function of enzymes, especially her work on tryptophan synthase.
References
- ↑ "Kern CV" (PDF). Archived (PDF) from the original on 2019-10-09.
- ↑ "Life Sciences Faculty - Dorothee Kern". www.bio.brandeis.edu. Retrieved 2018-03-25.
- 1 2 3 Curry, Andrew: "Big Dreams Come True", Science, 326:792
- ↑ Tong, Amber (July 16, 2020). "Relay reaps $400M IPO windfall after drawing the curtain on motion-based drug design pipeline". Endpoints News. Archived from the original on 2020-07-18. Retrieved 2021-09-17.
- 1 2 3 "Our Team". Relay Therapeutics. Retrieved 2021-09-14.
- ↑ "Dorothee Kern's path from basketball star to founder of billion-dollar biotech(s?); Five Prime Therapeutics hands the reins to Genentech vet". Endpoints News. April 17, 2020. Archived from the original on 2020-04-20. Retrieved 2021-09-17.
- 1 2 "Dorothee Kern". German Academy of Sciences Leopoldina. Retrieved 26 May 2021.
- ↑ "Leopoldina Mission Statement". Nationale Akademie der Wissenschaften Leopoldina. Retrieved 2021-11-21.
- 1 2 3 4 5 6 7 "Choreographing a Cancer Treatment". Brandeis Magazine. Retrieved 2021-11-26.
- 1 2 3 4 "Dorothee Kern | Brandeis University". www.brandeis.edu. Retrieved 2021-11-26.
- ↑ "Nadja Kern - 2014-15 - Women's Basketball".
- ↑ Eisenmesser, Elan Zohar; Bosco, Daryl A.; Akke, Mikael; Kern, Dorothee (2002). "Enzyme Dynamics during Catalysis". Science. 295 (5559): 1520–1523. Bibcode:2002Sci...295.1520E. doi:10.1126/science.1066176. JSTOR 3076038. PMID 11859194. S2CID 28841021.
- ↑ Kern, D. (1997-01-03). "How Thiamin Diphosphate Is Activated in Enzymes". Science. 275 (5296): 67–70. doi:10.1126/science.275.5296.67. PMID 8974393. S2CID 42796172.
- ↑ Kern, Dorothee; Zuiderweg, Erik RP (2003). "The role of dynamics in allosteric regulation". Current Opinion in Structural Biology. 13 (6): 748–757. doi:10.1016/j.sbi.2003.10.008. PMID 14675554.
- ↑ "Who We Are". Relay Therapeutics. Retrieved 2021-11-26.
- ↑ Nguyen, Vy; Wilson, Christopher; Hoemberger, Marc; Stiller, John B.; Agafonov, Roman V.; Kutter, Steffen; English, Justin; Theobald, Douglas L.; Kern, Dorothee (2017-01-20). "Evolutionary drivers of thermoadaptation in enzyme catalysis". Science. 355 (6322): 289–294. Bibcode:2017Sci...355..289N. doi:10.1126/science.aah3717. ISSN 0036-8075. PMC 5649376 . PMID 28008087.
- ↑ "Team". MOMA Therapeutics. Retrieved 2021-11-26.
- ↑ "MOMA Therapeutics: Drugging the molecular machines that underlie human disease". MOMA Therapeutics. 2020-04-11. Retrieved 2021-11-26.
